Article by: www.wealthblueprintletter.com, 2/19/2015
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins for gene regulation and gene modification in the United States. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Take a look at the 1-year chart of Sangamo (Nasdaq: SGMO) below with my added notations:
Other than the steep decline in March and April, SGMO has been trending primarily sideways over the last year. During that time stock has created an obvious resistance level at $17 (red). A break above that $17 level should mean higher prices for the stock.
The Tale of the Tape: SGMO has a key level of resistance at $17. A long trade could be entered on a break through that level. However, if you are bearish on the stock, a short trade could be made on any rallies up to $17.
Before making any trading decision, decide which side of the trade you believe gives you the highest probability of success. Do you prefer the short side of the market, long side, or do you want to be in the market at all? If you haven’t thought about it, review the overall indices themselves. For example, take a look at the S&P 500. Is it trending higher or lower? Has it recently broken through a key resistance or support level? Making these decisions ahead of time will help you decide which side of the trade you believe gives you the best opportunities.
No matter what your strategy or when you decide to enter, always remember to use protective stops and you’ll be around for the next trade. Capital preservation is always key!
Christian Tharp, CMT
Follow me on Twitter: